Welcome to STN International! Enter x:x

LOGINID: SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
         JUL 02
                 LMEDLINE coverage updated
NEWS
         JUL 02
                 SCISEARCH enhanced with complete author names
NEWS
         JUL 02
                 CHEMCATS accession numbers revised
NEWS
      5
         JUL 02
                 CA/CAplus enhanced with utility model patents from China
         JUL 16
NEWS
      6
                 CAplus enhanced with French and German abstracts
NEWS
      7
         JUL 18
                 CA/CAplus patent coverage enhanced
NEWS
      8
         JUL 26
                 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS
     9
         JUL 30
                USGENE now available on STN
NEWS 10
         AUG 06
                 CAS REGISTRY enhanced with new experimental property tags
NEWS 11
         AUG 06
                 FSTA enhanced with new thesaurus edition
         AUG 13
NEWS 12
                 CA/CAplus enhanced with additional kind codes for granted
                 patents
NEWS 13 AUG 20
                 CA/CAplus enhanced with CAS indexing in pre-1907 records
        AUG 27
NEWS 14
                 Full-text patent databases enhanced with predefined
                 patent family display formats from INPADOCDB
NEWS 15 AUG 27
                 USPATOLD now available on STN
NEWS 16
        AUG 28
                 CAS REGISTRY enhanced with additional experimental
                 spectral property data
NEWS 17
         SEP 07
                 STN AnaVist, Version 2.0, now available with Derwent
                 World Patents Index
NEWS 18
         SEP 13
                 FORIS renamed to SOFIS
NEWS 19
         SEP 13
                 INPADOCDB enhanced with monthly SDI frequency
         SEP 17
NEWS 20
                 CA/CAplus enhanced with printed CA page images from
                 1967-1998
NEWS 21
         SEP 17
                 CAplus coverage extended to include traditional medicine
                 patents
NEWS 22
         SEP 24
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23
         OCT 02
                 CA/CAplus enhanced with pre-1907 records from Chemisches
                 Zentralblatt
NEWS 24
         OCT 19
                 BEILSTEIN updated with new compounds
NEWS EXPRESS
              19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0jc(jp),
              AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
              Welcome Banner and News Items
NEWS IPC8
              For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

*IMSDRUGNEWS - IMS Drug News 1991-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 12:54:27 ON 20 OCT 2007

=> File .Gerry2MBCE
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:54:54 ON 20 OCT 2007

FILE 'BIOSIS' ENTERED AT 12:54:54 ON 20 OCT 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:54:54 ON 20 OCT 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:54:54 ON 20 OCT 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> S Activated(2A)alpha2-microglobulin (L)Fatty(A)acid AND pd<=20031230 1 FILES SEARCHED...

L1 0 ACTIVATED(2A) ALPHA2-MICROGLOBULIN (L) FATTY(A) ACID AND PD<=200 31230

=> Log off h
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:57:48 ON 20 OCT 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAEGS1646

PASSWORD:

* ** * * * RECONNECTED TO STN INTERNATIONAL * * * * * * SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' AT 12:59:28 ON 20 OCT 2007

FILE 'MEDLINE' ENTERED AT 12:59:28 ON 20 OCT 2007

FILE 'BIOSIS' ENTERED AT 12:59:28 ON 20 OCT 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:59:28 ON 20 OCT 2007

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:59:28 ON 20 OCT 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 15.71 15.92

FULL ESTIMATED COST

=> D Hist

(FILE 'HOME' ENTERED AT 12:54:27 ON 20 OCT 2007)

- FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 12:54:54 ON 20 OCT 2007
 L1 0 S ACTIVATED(2A)ALPHA2-MICROGLOBULIN (L)FATTY(A)ACID AND PD<=200
- => S ACTIVATED(2A)ALPHA2-MACROGLOBULIN (L)FATTY(A)ACID AND PD<=20031230 2 FILES SEARCHED...
- L2 2 ACTIVATED(2A) ALPHA2-MACROGLOBULIN (L) FATTY(A) ACID AND PD<=200 31230

=> D Ti L2 1-2

- L2 ANSWER 1 OF 2 MEDLINE on STN
- TI Fatty acids modulate transforming growth factor-beta activity and plasma clearance.
- L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma.

=> D ibib abs 12 2

L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:243873 BIOSIS DOCUMENT NUMBER: PREV200300243873

TITLE: Adipocyte low density lipoprotein receptor-related protein

gene expression and function is regulated by peroxisome

proliferator-activated receptor gamma.

AUTHOR(S): Gauthier, Andre; Vassiliou, Gerard; Benoist, Fabienne;

McPherson, Ruth [Reprint Author]

CORPORATE SOURCE: University of Ottawa, 40 Ruskin St., Rm. H441, Ottawa, K1Y

4W7, Canada

rmcpherson@ottawaheart.ca

SOURCE: Journal of Biological Chemistry, (April 4 2003)

Vol. 278, No. 14, pp. 11945-11953. print.

CODEN: JBCHA3. ISSN: 0021-9258.

DOCUMENT TYPE: LANGUAGE: Article English

ENTRY DATE: Entered

DATE: Entered STN: 21 May 2003
Last Undated on STN: 21 May 2003

Last Updated on STN: 21 May 2003 AΒ The alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) is a large multifunctional receptor that interacts with a variety of molecules. It is implicated in biologically important processes such as lipoprotein metabolism, neurological function, tissue remodeling, protease complex clearance, and cell signal transduction. However, the regulation of LRP gene expression remains largely unknown. In this study, we have analyzed 2 kb of the 5'-flanking region of the LRP gene and identified a predicted peroxisome proliferator response element (PPRE) from -1185 to -1173. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha2-macroglobulin binding and degradation. These agents were found to increase LRP transcription. Gel shift analysis of the putative PPRE demonstrated direct binding of PPARgamma/retinoid X receptor alpha heterodimers to the PPRE in the LRP gene. Furthermore, these heterodimers could no longer interact with a mutated PPRE probe. The isolated promoter was functional in SW872 cells, and its activity was increased by 1.5-fold with the addition of rosiglitazone. Furthermore, the isolated response element was similarly responsive to rosiglitazone when placed upstream of an ideal promoter. Mutagenesis of the predicted PPRE abolished the ability of this construct to respond to rosiglitazone. These data demonstrate that fatty acids and rosiglitazone directly stimulate

transcription of the LRP gene through activation of PPARgamma and increase

functional LRP expression.

=> Log off H

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:02:32 ON 20 OCT 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * * SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE'

AT 14:49:19 ON 20 OCT 2007

FILE 'MEDLINE' ENTERED AT 14:49:19 ON 20 OCT 2007

FILE 'BIOSIS' ENTERED AT 14:49:19 ON 20 OCT 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:49:19 ON 20 OCT 2007 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:49:19 ON 20 OCT 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

COST IN U.S. DOLLARS

SINCE FILE ENTRY

TOTAL SESSION

FULL ESTIMATED COST

34.14 34.35

=> D Hist

Ll

(FILE 'HOME' ENTERED AT 12:54:27 ON 20 OCT 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 12:54:54 ON 20 OCT 2007

0 S ACTIVATED (2A) ALPHA2-MICROGLOBULIN (L) FATTY (A) ACID AND PD<=200

L22 S ACTIVATED (2A) ALPHA2-MACROGLOBULIN (L) FATTY (A) ACID AND PD<=20

=> S Fatty(2A)Acid (S) TGFbeta AND pd<=20031230

2 FILES SEARCHED...

5 FATTY(2A) ACID (S) TGFBETA AND PD<=20031230 L3

=> D ibib abs L3 1-5

L3 ANSWER 1 OF 5 MEDLINE on STN

ACCESSION NUMBER: 2001301806 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11246816 TITLE:

Fat cell function and fibrinolysis. AUTHOR: Alessi M C; Morange P; Juhan-Vague I

CORPORATE SOURCE: Laboratory of Hematology, Faculty of Medicine, CHU Timone,

Marseille, France.

SOURCE: Hormone and metabolic research. Hormon- und

Stoffwechselforschung. Hormones et metabolisme, (2000

Nov-Dec) Vol. 32, No. 11-12, pp. 504-8. Ref: 62

Journal code: 0177722. ISSN: 0018-5043.

PUB. COUNTRY: Germany: Germany, Federal Republic of DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

Priority Journals FILE SEGMENT:

ENTRY MONTH: 200105

Entered STN: 4 Jun 2001 ENTRY DATE:

Last Updated on STN: 4 Jun 2001

Entered Medline: 31 May 2001

AB Plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of plasminogen activators and may be the principal regulator of plasminogen activation in vivo. PAI-1 levels are elevated in insulin-resistant subjects and are associated with an increased risk of atherothrombosis. After adjustment for metabolic parameters, increased PAI-1 levels were no longer considered as a cardiovascular risk factor. The mechanisms underlying the strong association between PAI-1 levels and the metabolic disturbances found in insulin resistance are still not understood. Several studies have suggested that visceral adipose tissue may be a major source of PAI-1. Accordingly, adipose tissue PAI-1 production particularly that from visceral fat, was found to be elevated in obese human subjects. Within human adipose tissue, stromal cells appear to be the main cells involved in PAI-1 synthesis. This review discusses the potential mechanisms linking adipose tissue to plasma PAI-1 levels such as the intervention of cytokines (TNFalpha and TGFbeta), free fatty acids and hormones (insulin and glucocorticoids). Moreover alteration of adipose tissue cellular composition induced by the modulation of PAI-1 expression opens a novel field of interest.

L3 ANSWER 2 OF 5 MEDLINE ON STN
ACCESSION NUMBER: 2001192510 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11204450

TITLE: Free radicals, cytokines and nitric oxide in cardiac

failure and myocardial infarction.

AUTHOR: Das U N

CORPORATE SOURCE: EFA Sciences LLC, Norwood, MA 02062, USA.

SOURCE: Molecular and cellular biochemistry, (2000 Dec)

Vol. 215, No. 1-2, pp. 145-52. Ref: 60 Journal code: 0364456. ISSN: 0300-8177.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200104

ENTRY DATE: Entered STN: 10 Apr 2001

Last Updated on STN: 10 Apr 2001 Entered Medline: 5 Apr 2001

AB Myocardial infarction is the most common cause of congestive cardiac failure. Free radicals, cytokines, nitric oxide (NO) and antioxidants play a major role both in atherosclerosis and myocardial damage and preservation. In the early stages of atherosclerosis, neutrophils and monocytes infiltrate the intima and generate free radicals which damage the endothelial cells. As a result, production of NO and prostacyclin by the endothelial cells declines, which have cardioprotective actions. also has relevance to the beneficial action of aspirin since, it can modulate both prostanoid and L-arginine-NO systems and NF-kB translocation. In both acute myocardial infarction and chronic congestive cardiac failure, the plasma levels of various inflammatory mediators such as interleukins and tumour necrosis factor-alpha (TNFalpha) are elevated. TNFalpha, produced by the inflammatory cells and the myocardium, can suppress myocardial contractility and induce the production of free radicals, which in turn can further damage the myocardium. Transforming growth factor beta (TGFbeta), polyunsaturated fatty acids and the glucose-insulin-potassium regimen can antagonize the harmful actions of TNFalpha and protect the myocardium. This explains why efforts made to reduce the levels of pro-inflammatory cytokines have beneficial action and preserve the myocardium.

L3 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:164234 BIOSIS DOCUMENT NUMBER: PREV200100164234

TITLE: Fat cell function and fibrinolysis.

AUTHOR(S): Alessi, M. C.; Morange, P.; Juhan-Vague, I. [Reprint

author]

CORPORATE SOURCE: Laboratory of Hematology, Faculty of Medicine, CHU Timone,

13385, Marseille Cedex 5, France

ijuhan@ap-hm.fr

SOURCE: Hormone and Metabolic Research, (November-December,

2000) Vol. 32, No. 11-12, pp. 504-508. print.

CODEN: HMMRA2. ISSN: 0018-5043.

DOCUMENT TYPE:

Article

General Review; (Literature Review)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 4 Apr 2001

Last Updated on STN: 15 Feb 2002

Plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of plasminogen activators and may be the principal regulator of plasminogen activation in vivo. PAI-1 levels are elevated in insulin-resistant subjects and are associated with an increased risk of atherothrombosis. After adjustment for metabolic parameters, increased PAI-1 levels were no longer considered as a cardiovascular risk factor. The mechanisms underlying the strong association between PAI-1 levels and the metabolic disturbances found in insulin resistance are still not understood. Several studies have suggested that visceral adipose tissue may be a major source of PAI-1. Accordingly, adipose tissue PAI-1 production particularly that from visceral fat, was found to be elevated in obese human subjects. Within human adipose tissue, stromal cells appear to be the main cells involved in PAI-1 synthesis. This review discusses the potential mechanisms linking adipose tissue to plasma PAI-1 levels such as the intervention of cytokines (TNFalpha and TGFbeta), free fatty acids and hormones (insulin and glucocorticoids). Moreover alteration of adipose tissue cellular composition induced by the modulation of PAI-1 expression opens a novel field of interest.

L3 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: DOCUMENT NUMBER: 2001:130453 BIOSIS PREV200100130453

TITLE:

Free radicals, cytokines and nitric oxide in cardiac

failure and myocardial infarction.

AUTHOR (S):

Das, U. N. [Reprint author]

CORPORATE SOURCE:

EFA Sciences LLC, Providence Highway, Suite No. 266,

Norwood, MA, 02062, USA

SOURCE:

Molecular and Cellular Biochemistry, (December,

2000) Vol. 215, No. 1-2, pp. 145-152. print.

CODEN: MCBIB8. ISSN: 0300-8177.

DOCUMENT TYPE:

Article

General Review; (Literature Review)

LANGUAGE:

English

ENTRY DATE:

Entered STN: 14 Mar 2001

Last Updated on STN: 15 Feb 2002

Myocardial infarction is the most common cause of congestive cardiac AB failure. Free radicals, cytokines, nitric oxide (NO) and antioxidants play a major role both in atherosclerosis and myocardial damage and preservation. In the early stages of atherosclerosis, neutrophils and monocytes infiltrate the intima and generate free radicals which damage the endothelial cells. As a result, production of NO and prostacyclin by the endothelial cells declines, which have cardioprotective actions. also has relevance to the beneficial action of aspirin since, it can modulate both prostanoid and L-arginine-NO systems and NF-kB translocation. In both acute myocardial infarction and chronic congestive cardiac failure, the plasma levels of various inflammatory mediators such as interleukins and tumour necrosis factor-alpha (TNFalpha) are elevated. TNFalpha, produced by the inflammatory cells and the myocardium, can suppress myocardial contractility and induce the production of free radicals, which in turn can further damage the myocardium. Transforming growth factor beta (TGFbeta), polyunsaturated fatty acids and the glucose-insulin-potassium regimen can antagonize the harmful actions of TNFalpha and protect the myocardium. This explains why efforts made to reduce the levels of pro-inflammatory cytokines have beneficial action and preserve the myocardium.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:606429 CAPLUS

DOCUMENT NUMBER:

139:240515

TITLE:

Fatty acids modulate transforming growth factor-β

activity and plasma clearance

AUTHOR(S):

Ling, Thai-Yen; Huang, Yen-Hua; Lai, Ming-Chih; Huang,

Shuan Shian; Huang, Jung San

CORPORATE SOURCE:

Inst. of Biomed. Sci., Acad. Sinica, Taipei, Taiwan

SOURCE:

FASEB Journal (2003), 17(11), 1559-1561,

10.1096/fj.02-1063fje

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER:

Federation of American Societies for Experimental

Biology

DOCUMENT TYPE:

Journal English

LANGUAGE:

AB The activity and plasma clearance of transforming growth factor (TGF)- β are known to be regulated by activated $\alpha 2$ -macroglobulin ($\alpha 2$ M*). This has been implicated in pathophysiol. processes, but no small mol. compds. have been reported to modulate TGF- β activity by affecting the interaction of TGF- β and $\alpha 2$ M*. Here, we demonstrate that fatty acids are capable of inhibiting complex formation of TGF- β isoforms and $\alpha 2$ M* as demonstrated by nondenaturing and SDS-PAGE. This is dependent on carbon chain length (C20, C18, C16, C14 >

C12 > C10), degree of unsatn. (polyunsatd. > saturated), and TGF- β isoforms (TGF- β 1 > TGF- β 2 > TGF- β 3). Arachidonic acid, which is one of the most potent inhibitors, is also capable of dissociating

TGF- β - α 2M* complexes, but higher concns. are required. Arachidonic acid appears to inhibit TGF- β - α 2M* complex

formation by binding specifically to $\alpha 2M^*$ as demonstrated by gel filtration chromatog. Arachidonic acid reverses the inhibitory effect of $\alpha 2M^*$ on TGF- β binding, TGF- β -induced growth inhibition, and TGF- β -induced transcriptional activation in mink lung epithelial cells and affects plasma clearance of TGF- β - $\alpha 2M^*$ complexes in

mice. These results show that fatty acids are effective modulators of TGF- β activity and plasma clearance and may be useful in treating human diseases through their effects on the interaction of TGF- β and $\alpha 2M^*$.

REFERENCE COUNT:

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> Log off H
SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:51:53 ON 20 OCT 2007